πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 416 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10444237

Anti-pancreatic cancer monoclonal antibody and use thereof

NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10413620

Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10407495

Bispecific antibody fragments for neurological disease proteins and methods of use

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391170

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10383945

Methods for DNA-dependent targeting of a cell permeant antibody

THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VERTERANS AFFAIRS Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376582

Buffer formulations for enhanced antibody stability

Outlook Therapeutics, Inc. Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10358481

Engineered antibody constant domain molecules

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10351628

Antibody fragments, compositions and uses thereof

METIS PRECISION MEDICINE SB S.R.L. Β· Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329338

Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon

The Regents of the University of Colorado Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10278986

Antibody-siRNA conjugates and uses therefor

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10273292

Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutrali

B Cell Design SAS Β· Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10266588

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10232042

Conjugates of an anti-TNF-alpha antibody

Nektar Therapeutics Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10197577

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10189901

Methods for improving cardiac function by administering an antibody that activates APLNR

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10166304

Antibody fragments for detecting cancer and methods of use

Regents of the University of Minnesota Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10149903

Fully human antibody against respiratory syncytical virus

ELITEIMMUNE INC. Β· Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10118961

Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV

CytomX Therapeutics, Inc. Β· Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10087240

DNA antibody constructs and method of using same

Inovio Pharmaceuticals, Inc. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10071168

Polyoxazoline antibody drug conjugates

Serina Therapeutics, Inc. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10072070

Potent anti-influenza A neuraminidase subtype N1 antibody

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10053514

Human bispecific EGFRvIII and CD3 antibody engaging molecules

The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health Β· Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10035848

Antibody targeting cell surface deposited complement protein C3d and use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted